866-997-4948(US-Canada Toll Free)

Inflammatory Bowel Disease (IBD) Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Published By :

Transparency Market Research

Published Date : Jan 2018

Category :

Pharmaceutical

No. of Pages : 207 Pages

Global Inflammatory Bowel Disease (IBD) Treatment Market: Overview

Inflammatory bowel disease is a group of medical indication that causes chronic inflammation in the gastrointestinal tract. The inflammatory bowel disease mainly comprises of Ulcerative colitis and Crohn’s disease. The ulcerative colitis primarily affects the large intestine and anus and it causes the inflammation sores in the inner lining of colon and rectum. The Crohn’s disease affects any part of gastrointestinal tract and unlike ulcerative colitis, it affects all the layers of gastrointestinal walls. The ulcerative colitis is more prevalent than that of Crohn’s disease. The IBD affects equally in men and women and has prevalence and incidence rates in developed countries than that of developing and under developed countries. The exact cause of inflammatory bowel disease are not well understood however, the combination of several factors such as autoimmune disorders, genetic factors, lifestyle related risks factors such as smoking, sedentary lifestyle, lack of exercise are likely to contribute to the development of symptoms of inflammatory bowel disease. The common symptoms of inflammatory bowel disease includes the severe abdominal cramps and pain, persistent diarrhea, occasional rectal bleeding. The IBD has no permanent cure and requires the lifelong disease management and treatment. Several medications such as corticosteroids, aminosalicyclates, immunomodulators, and biologic drugs such as TNF inhibitors and up to certain extent antibiotic drugs are prescribed to relive the symptoms of these diseases.

Global Inflammatory Bowel Disease (IBD) Treatment Market: Trends and Opportunities

The global IBD treatment market is projected to be primarily driven by the new product development and approvals, rising use of biologic drugs and biosimilar drugs for the treatment of IBD. The high prevalence and increasing incidence of Crohn’s disease and Ulcerative colitis disease in developed countries has fueled the development of novel therapeutics drugs. Genetic factors are found to induce the one of the forms of IBD. The children of parents having IBD are more likely to develop the symptoms of IBD. Studies have shown that around 5 to 20 % of affected population have developed the symptoms of IBD through inherited genes from parents. The Risk of developing IBD is higher when both the parents are affected with IBD. Biopharmaceutical companies have made the significant investments in R&D activities and there are large number of pipeline products in different stages of clinical approvals which are likely to commercialize during the forecast period.  Recent launch and approvals of new drugs in North America and Europe as well as in Japan is projected to fuel the demand for IBD treatment drugs in near future.

Global Inflammatory Bowel Disease (IBD) Treatment Market: Key Segments

The global IBD treatment market is broadly categorized into four segments based on drug class, disease indication, distribution channel and region. By drug class, the global market is segmented into TNF inhibitors, aminosalicyclates, immunomodulators, and corticosteroids. The TNF inhibitors accounted for leading share of global IBD treatment market in 2016 and is projected to gain its market share by the end of 2025. The large share and growth of TNF inhibitors is attributed to rising use of biologic drugs as second line of treatment and approvals in key markets. Aminosalicyclates drug class is the second leading share holder of global IBD treatment market and is projected to substantially lose its market share to corticosteroids and immunomodulators during the forecast period.  In terms of distribution channel, the global IBD treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

By geography, the global IBD treatment market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. These regions have been further segmented by countries, drug class, and disease indication and distribution channels. North America and Europe accounted for leading share of global IBD treatment market and are projected to gain the market share by the end of 2025.

Global Inflammatory Bowel Disease (IBD) Treatment Market: Competitive Outlook k

The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global inflammatory bowel disease treatment market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc.

Global Inflammatory Bowel Disease Treatment Market is segmented as given below:

Global Inflammatory Bowel Disease Treatment Market, by Drug Class

  • TNF Inhibitors
  • Aminosalicyclates
  • Immunomodulators
  • Corticosteroids

Global Inflammatory Bowel Disease Treatment Market, by Disease Indication

  • Ulcerative Colitis
  • Crohn’s Disease

Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Global Inflammatory Bowel Disease Treatment Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Table of Content

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Inflammatory Bowel Disease (IBD) Treatment market  

Chapter 4. Market Overview
4.1. Introduction
4.2. Key Industry Developments

Chapter 5. Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Porter’s five forces analysis
5.5. Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, 2015–2025
5.6. Global Inflammatory Bowel Disease (IBD) Treatment Market Outlook
5.7. Global Prevalence of Ulcerative Colitis
5.8. Global Prevalence of Crohn’s Disease
5.9. Pipeline Analysis

Chapter 6. Inflammatory Bowel Disease (IBD) Treatment Market Analysis and Forecast, by Drug Class
6.1. Key Findings 
6.2. Introduction 
6.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
6.3.1. TNF Inhibitors
6.3.2. Aminosalicyclates
6.3.3. Immunomodulators
6.3.4. Corticosteroids
6.4. Market Attractiveness Analysis, by Drug Class
6.5. Key Trends

Chapter 7. Global Inflammatory Bowel Disease (IBD) Treatment Market Analysis and Forecasts, by Disease Indication
7.1. Key Findings
7.2. Introduction
7.3. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
7.3.1. Ulcerative Colitis
7.3.2. Crohn’s Disease
7.4. Market Attractiveness Analysis, by Disease Indication
7.5. Key Trends

Chapter 8. Global Inflammatory Bowel Disease (IBD) Treatment Market Analysis and Forecasts, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy 
8.4. Market Attractiveness Analysis, by Distribution Channel
8.5. Key Trends

Chapter 9. Global Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2017-2025
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific 
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis, by Region
9.5. Key Trends, By Region

Chapter 10. North America Inflammatory Bowel Disease (IBD) Treatment market Analysis andForecast
10.1. Key Findings 
10.2. Market size (US$ Mn) Forecast, by Country, 2017-2025
10.2.1. U.S.
10.2.2. Canada
10.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
10.3.1. TNF Inhibitors
10.3.2. Aminosalicyclates
10.3.3. Immunomodulators
10.3.4. Corticosteroids
10.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
10.4.1. Ulcerative Colitis
10.4.2. Crohn’s Disease 
10.5. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Attractiveness Analysis 
10.6.1. By Country
10.6.2. By Drug Class
10.6.3. By Disease Indication
10.6.4. By Distribution Channel

Chapter 11. Europe Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecast
11.1. Key Findings 
11.2. Market size (US$ Mn) Forecast By Country/Sub-region, 2017-2025
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
11.3.1. TNF Inhibitors
11.3.2. Aminosalicyclates
11.3.3. Immunomodulators
11.3.4. Corticosteroids
11.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
11.4.1. Ulcerative Colitis
11.4.2. Crohn’s Disease 
11.5. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy
11.5.3. Online Pharmacy
11.6. Market Attractiveness Analysis 
11.6.1. By Country/Sub-region
11.6.2. By Drug Class
11.6.3. By Disease Indication
11.6.4. By Distribution Channel

Chapter 12. Asia Pacific Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
12.4.1. TNF Inhibitors
12.4.2. Aminosalicyclates
12.4.3. Immunomodulators
12.4.4. Corticosteroids
12.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
12.5.1. Ulcerative Colitis
12.5.2. Crohn’s Disease 
12.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
12.6.1. Hospital Pharmacy
12.6.2. Retail Pharmacy
12.6.3. Online Pharmacy
12.7. Market Attractiveness Analysis 
12.7.1. By Country/Sub-region
12.7.2. By Drug Class
12.7.3. By Disease Indication
12.7.4. By Distribution Channel

Chapter 13. Latin America Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market Size (US$ Mn) Forecast, by Country, 2017-2025
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
13.4.1. TNF Inhibitors
13.4.2. Aminosalicyclates
13.4.3. Immunomodulators
13.4.4. Corticosteroids
13.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
13.5.1. Ulcerative Colitis
13.5.2. Crohn’s Disease 
13.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
13.6.1. Hospital Pharmacy
13.6.2. Retail Pharmacy
13.6.3. Online Pharmacy
13.7. Market Attractiveness Analysis 
13.7.1. By Country/Sub-region
13.7.2. By Drug Class
13.7.3. By Disease Indication
13.7.4. By Distribution Channel

Chapter 14. Middle East and Africa Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East and Africa
14.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
14.4.1. TNF Inhibitors
14.4.2. Aminosalicyclates
14.4.3. Immunomodulators
14.4.4. Corticosteroids
14.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
14.5.1. Ulcerative Colitis
14.5.2. Crohn’s Disease 
14.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
14.6.1. Hospital Pharmacy
14.6.2. Retail Pharmacy
14.6.3. Online Pharmacy
14.7. Market Attractiveness Analysis 
14.7.1. By Country/Sub-region
14.7.2. By Drug Class
14.7.3. By Disease Indication
14.7.4. By Distribution Channel

Chapter 15. Competition Landscape
15.1. Global Inflammatory Bowel Disease (IBD) Treatment Market Share, by Company, 2016
15.2. Market Player – Competition Matrix (By Tier and Size of companies)
15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.3.1. Shire plc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

15.3.2. Pfizer, Inc. 

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

15.3.3. Janssen Biotech, Inc. (Johnson & Johnson)

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.4. Valeant Pharmaceuticals International, Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.5. Allergan plc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.6. Takeda Pharmaceutical Company Limited. 

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.7. AbbVie, Inc. 

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.8. Novartis AG

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.9. UCB Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.10. Biogen Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

List of Table

Table 01: Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 02: Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 03: Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 04: Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 05: North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 06: North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 07: North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 08: North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 09: Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 10: Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 11: Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 12: Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 14: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 15: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 16: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 17: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 18: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 19: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 20: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 21: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 22: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 23: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 24: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025

List of Chart

Figure 01: Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, 2015–  2025
Figure 02: Market Value Share, by Drug Class (2016)
Figure 03: Market Value Share, by Disease Indication (2016)
Figure 04: Market Value Share, by Distribution Channel (2016)
Figure 05: Market Value Share, by Country (2016)
Figure 06: Global Inflammatory Bowel Disease (IBD) Treatment Market Value Share analysis, by Drug Class, 2016 and 2025
Figure 07: Global Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 08: Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by TNF Inhibitors, 2015–2025
Figure 09: Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Aminosalicyclates, 2015–2025
Figure 10: Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Immunomodulators, 2015–2025
Figure 11: Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2015–2025
Figure 12: Global Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Disease Indication, 2016 and 2025
Figure 13: Global Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 14: Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Ulcerative Colitis, 2015–2025
Figure 15: Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Crohn’s Disease, 2015–2025
Figure 16: Global Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Distribution channel, 2016 and 2025
Figure 17: Global Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness, by Distribution channel, 2017–2025
Figure 18: Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2015–2025
Figure 19: Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
Figure 20: Global Inflammatory Bowel Disease (IBD) Treatment Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2015-2025
Figure 21: Global Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Region, 2016 and 2025 
Figure 22: Global Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Region, 2017–2025
Figure 23: North America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 24: North America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Country, 2016 and 2025
Figure 25: North America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Country, 2017-2025
Figure 26: North America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 27: North America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Disease Indication, 2016 and 2025
Figure 28: North America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 29: North America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 30: North America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 31: North America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 32: Europe Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 33: Europe Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 34: Europe Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
Figure 35: Europe Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 36: Europe Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Disease Indication, 2016 and 2025
Figure 37: Europe Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 38: Europe Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 39: Europe Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 40: Europe Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 41: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 42: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 43: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
Figure 44: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 45: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Disease Indication, 2016 and 2025
Figure 46: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 47: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 48: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 49: Asia Pacific Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 50: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 51: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 52: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
Figure 53: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 54: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Disease Indication, 2016 and 2025
Figure 55: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 56: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 57: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 58: Latin America Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 59: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 60: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 61: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2017-2025
Figure 62: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 63: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Disease Indication, 2016 and 2025
Figure 64: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 65: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 66: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 67: Middle East & Africa Inflammatory Bowel Disease (IBD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 68: Global Inflammatory Bowel Disease (IBD) Treatment Market Share Analysis, by Company (2016)
Figure 69: Shire Plc.’s Breakdown of Net Sales, by Business Segment
Figure 70: Shire Plc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2016
Figure 71: Shire Plc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 72: Pfizer Inc.’s Breakdown of Net Sales, by Region, 2016
Figure 73: Pfizer Inc.’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 74: Pfizer Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 75: Jonson & Johnson’s Breakdown of Net Sales, by Region, 2016
Figure 76: Jonson & Johnson’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 77: Jonson & Johnson’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 78: Valeant Pharmaceutical's Breakdown of Net Sales, by Region, 2016
Figure 79: Valeant Pharmaceutical's Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2016
Figure 80: Valeant Pharmaceutical's R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 81: Allergan Plc.’s Breakdown of Net Sales, by Business Segment
Figure 82: Allergan Plc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2016
Figure 83: Allergan Plc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 84: Takeda Pharmaceutical’s Breakdown of Net Sales, by Region
Figure 85: Takeda Pharmaceutical’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2016
Figure 86: Takeda Pharmaceutical’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 87: AbbVie Inc.’s Breakdown of Net Sales, by Region
Figure 88: AbbVie Inc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 89: AbbVie Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 90: Novartis AG’s Breakdown of Net Sales, by Region
Figure 91: Novartis AG’s Breakdown of Net Sales, by Business Segment
Figure 92: Novartis AG’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2016
Figure 93: Novartis AG’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 94: UCB Inc.’s Breakdown of Net Sales, by Region
Figure 95: UCB Inc.’s Breakdown of Net Sales, by Therapeutic Areas
Figure 96: UCB Inc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2016
Figure 97: UCB Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 98: Biogen Inc.’s Breakdown of Net Revenue, by Region
Figure 99: Biogen Inc.’s Breakdown of Net Sales, by Revenue Centers
Figure 100: Biogen Inc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 101: Biogen Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *